News
-
-
-
-
-
-
-
PRESS RELEASE
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization
Xlife Sciences AG released its Half-Year Report 2025 with focus on VERAXA Biotech AG's NASDAQ listing and internationalization. Operational and financial highlights were shared along with clear priorities for H2 2025 -
PRESS RELEASE
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need -
-